Yale Spinout, Cybrexa Therapeutics, to Debut Preclinical Data Demonstrating CBX-15 is Safe and Highly Efficacious in 13762 Triple Negative Breast Cancer Model
Source:
|
Date:
10/12/2023
Yale Spinout, Cybrexa Therapeutics, to Debut Preclinical Data Demonstrating CBX-15 is Safe and Highly Efficacious in 13762 Triple Negative Breast Cancer Model
